ES-SCLC Patients with PD-L1 + CTCs and High Percentages of CD8 + PD-1 + T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment.
- Resource Type
- Article
- Source
- Biomedicines; Jan2024, Vol. 12 Issue 1, p146, 11p
- Subject
PROGRAMMED cell death 1 receptors T cells PROGRAMMED death-ligand 1 BLOOD circulation CD8 antigen - Language
- ISSN
- 22279059